What is the patient quality of life on the SUCCESOR-2 trial?
To ensure long-term clinical efficacy and treatment compliance, avoiding severe off-target side effects is vital to maintaining patient well-being, Prof. Weisel stressed. "We
Focus on CELMoDs
EHA 2026
Meetings / Conferences
Multiple Myeloma
Roundtable Discussions
Video Interviews
Myeloproliferative Neoplasms
Polycythemia Vera
News
FDA approves ropeginterferon alfa-2b-njft pen for polycythemia vera
The US Food and Drug Administration has approved and launched a new prefilled pen device for ropeginterferon alfa-2b-njft (BESREMi Pen) for adult patients
Focus on CELMoDs
EHA 2026
Meetings / Conferences
Multiple Myeloma
Roundtable Discussions
Video Interviews
How to sequence mezigdomide-based therapy in myeloma?
In this multiple myeloma roundtable from EHA 2026, the roundtable panelists evaluate the strategic sequencing of mezigdomide-based therapy, its potential as a bridging
Leukemia
Acute Lymphoblastic Leukemia
News
FDA approves allogeneic regulatory T cell-based immunotherapy for hematologic malignancies
The therapeutic indication covers patients undergoing matched donor hematopoietic stem cell transplantation (HSCT) alongside a myeloablative preparative regimen to facilitate immunologic reconstitution and
Focus on CELMoDs
EHA 2026
Meetings / Conferences
Multiple Myeloma
Roundtable Discussions
Video Interviews
Where do CELMoDs, including mezigdomide and iberdomide, fit in the myeloma treatment landscape?
Clinical investigators are actively evaluating these novel agents across several strategic combinations and settings, Prof. Weisel explained. "We have very interesting maintenance trials,"
Focus on CELMoDs
EHA 2026
Meetings / Conferences
Multiple Myeloma
Roundtable Discussions
Video Interviews
What is the phase 3 SUCCESSOR-2 trial?
Dr. Dimopoulos reviews the clinical efficacy of adding the novel cereblon E3 ligase modulator (CELMoD), mezigdomide, to carfilzomib and dexamethasone (MeziKd) for patients
Lymphoma
Mantle Cell Lymphoma
News
China NMPA grants accelerated approval to rocbrutinib in relapsed or refractory mantle cell lymphoma
The NMPA approval was based on data from the phase 2 ROCK-1 study evaluating rocbrutinib monotherapy in patients with MCL who had relapsed
Lymphoma
Aggressive B-Cell Lymphomas
News
Tafasitamab combo approved in Japan for relapsed, refractory DLBCL
The clinical approval was based on data from the international phase 2 L-MIND trial and the domestic phase 1b/2 J-MIND trial in Japan.
Myeloproliferative Neoplasms
Polycythemia Vera
Taiwan regulatory body approves ropeginterferon alfa-2b-njft in ET
Taiwan’s Ministry of Health and Welfare has approved ropeginterferon alfa-2b-njft (BESREMi) for adult patients with essential thrombocythemia, according to PharmaEssentia, the manufacturer of
Multiple Myeloma
News
CHMP recommends approval of isatuximab subcutaneous formulation for MM
The recommendation was based on results from the phase 3 IRAKLIA trial, which demonstrated that the subcutaneous formulation was noninferior to intravenous administration